Mutual of America Capital Management LLC Has $614,000 Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Mutual of America Capital Management LLC raised its holdings in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 2.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,807 shares of the biotechnology company’s stock after purchasing an additional 751 shares during the period. Mutual of America Capital Management LLC’s holdings in ADMA Biologics were worth $614,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the stock. State Street Corp raised its position in shares of ADMA Biologics by 61.4% during the third quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock worth $259,970,000 after purchasing an additional 4,945,063 shares during the period. Geode Capital Management LLC grew its stake in ADMA Biologics by 2.6% in the third quarter. Geode Capital Management LLC now owns 5,381,985 shares of the biotechnology company’s stock valued at $107,606,000 after purchasing an additional 137,989 shares in the last quarter. Perpetual Ltd acquired a new position in shares of ADMA Biologics during the 4th quarter worth about $62,300,000. Lord Abbett & CO. LLC acquired a new position in shares of ADMA Biologics in the third quarter valued at $61,858,000. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of ADMA Biologics by 1,144.4% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 2,841,849 shares of the biotechnology company’s stock valued at $51,016,000 after acquiring an additional 2,613,482 shares during the period. 75.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price objective on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Trading Up 0.7 %

Shares of ADMA stock opened at $17.02 on Monday. The stock has a 50 day simple moving average of $16.66 and a two-hundred day simple moving average of $17.96. The company has a market cap of $4.02 billion, a P/E ratio of 60.79 and a beta of 0.60. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a fifty-two week low of $5.88 and a fifty-two week high of $23.64.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.